Abstract
From the dualistic classification that divides endometrial cancer (EC) into two types with distinct underlying molecular profiling, histopathology and clinical behavior, arises a deeper understanding of the carcinogenesis pathways. EC treatment comprises different and multimodal therapeutic approaches, such as chemotherapy, radiation therapy or combinations of novel drugs; however, few of these regimens have truly improved progression-free or survival rates in advanced and metastatic settings.
| Lingua originale | English |
|---|---|
| pagine (da-a) | 497-509 |
| Numero di pagine | 13 |
| Rivista | Expert Opinion on Emerging Drugs |
| Volume | 19 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2014 |
Keywords
- biomarker
- endometrial cancer
- molecular pathway
- target therapy